ArticleResearch and practice in thrombosis and haemostasis2025
Optimization of a Western blot protocol for the detection of low levels of tissue factor in human cells.
Article in Research and practice in thrombosis and haemostasis, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Tissue factor detection in mouse tissues by western blotting using commercial antibodies.Research and practice in thrombosis and haemostasis · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: The tissue factor (TF)/activated factor VII complex is the major activator of the coagulation system. TF is expressed by a variety of cells, including activated monocytes and tumor cells. Increased TF expression can cause thrombosis in different diseases, including sepsis, viral infections, and cancer. We have previously described a method for analyzing human TF in high-expressing cells by Western blotting. Objectives: The goal of this study was to establish a method for detecting human TF in low-expressing cells. Methods: We examined the ability of 3 different antibodies to detect TF in low-expressing cell lines: rabbit polyclonal anti-human TF antibody NBP2-15139 (Novus Biologicals), goat polyclonal anti-human TF antibody AF2339 (R&D Systems), and rabbit monoclonal anti-human TF antibody ab252918 (clone EPR22548-240; Abcam). We also used the Abcam antibody to measure TF expression in lipopolysaccharide-stimulated peripheral blood mononuclear cells. Results: We found that sensitivity was affected by various factors, including the blocking conditions, the detection method, and the primary and secondary antibodies. Both the R&D and Abcam antibodies were more specific in assessing TF expression than the Novus antibody; however, the Abcam antibody was the best of the 3 in evaluating TF in low-expressing cell lines. We detected TF in lipopolysaccharide-stimulated human peripheral blood mononuclear cells using the new method with the Abcam antibody. Conclusion: Researchers should consider each step in Western blotting when establishing a method for detecting low-abundance antigens, such as TF.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.